Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors

Research report (imported) 2018 - Max Planck Institute for Molecular Genetics

Authors
Risch, Thomas; Abdavi-Azar, Nilofar; Jandrasits, Christine; Amstislavskiy, Vyacheslav; Worth, Catherine L.; Warnatz, Hans-Jörg; Sultan, Marc; Herwig, Ralf; Lehrach, Hans; Yaspo, Marie-Laure; in Kooperation mit dem OncoTrack Konsortium (www.oncotrack.eu)
Departments
Vertebraten-Genomik
Summary
Colorectal carcinomas (CRC) are clinically challenging tumors. To identify novel predictive biomarkers of the therapeutic response, the OncoTrack consortium recruited 106 CRC patients for establishing a biobank of organoids and xenografts models analysed by sequencing and tested in a pre-clinical platform. This unique resource generated a compendium of data for advancing our understanding of CRC. Linking molecular patterns with drug response profiles identified novel biomarkers, including a signature outperforming RAS/RAF mutations in predicting sensitivity to the EGFR inhibitor cetuximab.

For the full text, see the German version.

Go to Editor View